Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.78 |
| ▸ | AURKA | O14965 | 1/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.77 |
| ▸ | INSR | P06213 | 1/20 | 0.77 |
| ▸ | FBP1 | P09467 | 1/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.77 |
| ▸ | FLT4 | P35916 | 1/20 | 0.77 |
| ▸ | CLK1 | P49759 | 1/20 | 0.77 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.77 |
| ▸ | TEK | Q02763 | 1/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102985 | 1.00 | EGFR (1.00) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL17520361 | 0.97 | EGFR (0.94) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL11113 | 0.95 | EGFR (1.00) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL10883 | 0.92 | EGFR (1.00) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL18435103 | 0.92 | EGFR (0.90) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL8789 | 0.91 | EGFR (0.84) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL14092460 | 0.90 | EGFR (0.92) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL31491085 | 0.90 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL30207668 | 0.90 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL28520911 | 0.90 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| EP-3181554-A1 | QUINAZOLINE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181554-A1 | QUINAZOLINE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023330-A1 | QUINAZOLINE DERIVATIVE | 石药集团中奇制药技术(石家庄)有限公司 | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774079-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | EGFR 3701/4885KDR 3669/4885AURKA 228/4885 |
| US-10421754-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | EGFR 3701/4885KDR 3669/4885AURKA 228/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | EGFR 3701/4885KDR 3669/4885AURKA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.